Ms. Lane has served for over 32 years on 15 boards, three of which were internationally based and several of which oversaw transformational change.  She is a qualified Financial Expert and a recognized expert in finance, compensation and governance. She has served on boards on both sides of activist campaigns and was on four boards as part of activist slates. 

Transformational Change—sitting on the Envestnet and Verisk boards to oversee structural and operational transformation; on the Willis board for 7 years, then selected to serve on the merged board of Willis Towers Watson to oversee the merger integration and subsequent growth of the merged company to its current market cap exceeding $25B.   Also selected to join MSCI’s board as part of an activist slate. While at MSCI, oversaw the development of a major strategic and business strategy shift and was deeply involved in capital allocation and capital expenditure approvals as well as C-level revisions and was central to the major restructuring of the accompanying compensation plan. The share price tripled in 2 ½ years, with a market cap exceeding $18.5B when she left the board.

At LabCorp, she joined in the midst of a regulatory suit that sent the shares into the single digits before the company recovered to become the premier diagnostic testing company in the US, including participating in its decision to acquire Covance to strengthen its position in personalized medicine and biopharma sciences.  On the board of Tyco, Ms. Lane helped to stabilize the company and select the new CEO and reviewed various control systems to preclude future problems. She was the one current director selected by the new board to help develop all of its governance policies and practices.  

Financial Expert—For 15 years, Ms. Lane was an investment banker at Goldman, Sachs & Co and then DLJ where she left as a Principal and Managing Director. She served a broad range of companies all across the globe and designed and oversaw the full range of transactions and advisory work, including IPOs, capital raises and mergers and acquisitions. Ms. Lane was lead banker on transactions for Orient Leasing, Advanced Micro Devices, Roche Holdings, Epsilon Data and other companies. She is a founding individual investor in several companies including but not limited to Staples, Dick’s Sporting Goods, and Skyhook and the initial leveraged buyout of 7-Up, and invests in the medtech and biotech industries. Her broad range of experience enables her to cross-fertilize ideas between companies and industries. 

Ms. Lane chaired LabCorp’s Audit Committee for 12 years, sat on the Audit Committee of WLTW and its predecessor for 12 years, founded and chairs the Audit and Risk Committee of private family held Saudi company Al-Dabbagh Group, and sat on the Audit Committee of UPM, a $16B Finnish paper, pulp and energy company, for 13 years.  She recently became the Lead Director of a Canadian fintech SPAC. 

Governance and Compensation Expert—Ms. Lane is a recognized expert in Governance and speaks at many venues, including those of the NACD, Council of International Investors, 13D Monitor, Harvard Business School, and Stanford Law School, among others.   

Ms. Lane chaired the Compensation Committee at Willis Towers Watson and its predecessor company through the merger and turnover of two CEOs. She chaired the Compensation Committee of LabCorp and sat on the Compensation Committee of MSCI.  In addition, Ms. Lane has served on Executive, CEO Search, and Strategic Alternatives Committee.